Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Animesh Barua is active.

Publication


Featured researches published by Animesh Barua.


International Journal of Gynecological Cancer | 2009

Histopathology of ovarian tumors in laying hens: a preclinical model of human ovarian cancer.

Animesh Barua; Pincas Bitterman; Jacques S. Abramowicz; Angela L. Dirks; Janice M. Bahr; Dale B. Hales; Michael J. Bradaric; Seby L. Edassery; Jacob Rotmensch; Judith L. Luborsky

The high mortality rate due to ovarian cancer (OVCA) is attributed to the lack of an effective early detection method. Because of the nonspecificity of symptoms at early stage, most of the OVCA cases are detected at late stages. This makes the access to women with early-stage disease problematic and presents a barrier to development and validation of tests for detection of early stage of OVCA in humans. Animal models are used to elucidate disease etiologies and pathogenesis that are difficult to study in humans. Laying hen is the only available animal that develops OVCA spontaneously; however, detailed information on ovarian tumor histology is not available. The goal of this study was to determine the histological features of malignant ovarian tumors in laying hens. A total of 155 young and old (1-5 years of age) laying hens (Gallus domesticus) were selected randomly and evaluated grossly and microscopically for the presence of ovarian tumors. Histological classification of tumors with their stages and grades was determined with reference to those for humans. Similar to humans, all 4 types including serous, endometrioid, mucinous, and clear cell or mixed carcinomas were observed in hen ovarian tumors. Some early neoplastic as well as putative ovarian lesions were also observed. Similarities in histology, metastasis, and stages of hen OVCA to those of humans demonstrate the feasibility of the hen model for additional delineation of the mechanism underlying ovarian carcinogenesis, preclinical testing of new agents for the prevention, and therapy of this disease.


American Journal of Reproductive Immunology | 2005

Anti-tumor antibodies in ovarian cancer.

Judith L. Luborsky; Animesh Barua; Seerin V. Shatavi; Tewabe Kebede; Jacques S. Abramowicz; Jacob Rotmensch

Anti‐tumor antibodies have potential as cancer biomarkers. There is relatively limited identification of anti‐tumor antibodies in response to ovarian cancer, compared with studies for other cancers. There is also very limited information on the prevalence of anti‐tumor antibodies among ovarian cancer patients. Although most anti‐tumor antibodies react with antigens common to both tumor and normal tissue, the anti‐tumor response tends to be confined to individuals with ovarian cancer, similar to other cancers. Antibodies to HOXA7, a differentiation antigen, have the highest reported prevalence in ovarian cancer (67%). Antibodies to other ubiquitous antigens including NY‐ESO‐1, Ep‐CAM (epithelial cell adhesion molecule), HSP‐90 (heat shock protein 90), and mutated p53 have been identified in ovarian cancer. Anti‐tumor antibody specificity reflects the heterogeneity of antigen expression in tumors. Tests based on panels of a combination of anti‐tumor antibodies may be more predictive for ovarian cancer, as no single specificity accounts for ovarian tumors. In addition to characterization of anti‐tumor antibodies as diagnostic markers, study of anti‐tumor antibodies is likely to provide insights into mechanisms of tumor development. There is evidence of antibodies to tumor antigens and of activated T cells, suggesting immune recognition of tumor antigens occurred. Nonetheless, as tumors are not ‘rejected’, it is likely that there are alterations in the immune system. The basis for tumor growth in the face of immune activity remains to be determined.


Journal of Ovarian Research | 2010

Differential expression of aldehyde dehydrogenase 1a1 (ALDH1) in normal ovary and serous ovarian tumors.

Krishna Penumatsa; Seby L. Edassery; Animesh Barua; Michael J. Bradaric; Judith L. Luborsky

BackgroundWe showed there are specific ALDH1 autoantibodies in ovarian autoimmune disease and ovarian cancer, suggesting a role for ALDH1 in ovarian pathology. However, there is little information on the ovarian expression of ALDH1. Therefore, we compared ALDH1 expression in normal ovary and benign and malignant ovarian tumors to determine if ALDH1 expression is altered in ovarian cancer. Since there is also recent interest in ALDH1 as a cancer stem cell (CSC) marker, we assessed co-expression of ALDH1 with CSC markers in order to determine if ALDH1 is a potential CSC marker in ovarian cancer.MethodsmRNA and protein expression were compared in normal human ovary and serous ovarian tumors using quantitative Reverse-Transcriptase PCR, Western blot (WB) and semi-quantitative immunohistochemistry (IHC). ALDH1 enzyme activity was confirmed in primary ovarian cells by flow cytometry (FC) using ALDEFLUOR assay.ResultsALDH1 mRNA expression was significantly reduced (p < 0.01; n = 5) in malignant tumors compared to normal ovaries and benign tumors. The proportion of ALDH1+ cells was significantly lower in malignant tumors (17.1 ± 7.61%; n = 5) compared to normal ovaries (37.4 ± 5.4%; p < 0.01; n = 5) and benign tumors (31.03 ± 6.68%; p < 0.05; n = 5). ALDH1+ cells occurred in the stroma and surface epithelium in normal ovary and benign tumors, although surface epithelial expression varied more in benign tumors. Localization of ALDH1 was heterogeneous in malignant tumor cells and little ALDH1 expression occurred in poorly differentiated malignant tumors. In benign tumors the distribution of ALDH1 had features of both normal ovary and malignant tumors. ALDH1 protein expression assessed by IHC, WB and FC was positively correlated (p < 0.01). ALDH1 did not appear to be co-expressed with the CSC markers CD44, CD117 and CD133 by IHC.ConclusionsTotal ALDH1 expression is significantly reduced in malignant ovarian tumors while it is relatively unchanged in benign tumors compared to normal ovary. Thus, ALDH1 expression in the ovary does not appear to be similar to breast, lung or colon cancer suggesting possible functional differences in these cancers.SignificanceThese observations suggest that reduced ALDH1 expression is associated with malignant transformation in ovarian cancer and provides a basis for further study of the mechanism of ALDH1 in this process.


Gynecologic Oncology | 2009

E-cadherin expression in ovarian cancer in the laying hen, Gallus domesticus, compared to human ovarian cancer

Kristine Ansenberger; Yan Zhuge; Jo Ann J. Lagman; Cassandra Richards; Animesh Barua; Janice M. Bahr; Dale B. Hales

OBJECTIVE Epithelial ovarian carcinoma (EOC) is a leading cause of cancer deaths in women. Until recently, a significant lack of an appropriate animal model has hindered the discovery of early detection markers for ovarian cancer. The aging hen serves as an animal model because it spontaneously develops ovarian adenocarcinomas similar in histological appearance to the human disease. E-cadherin is an adherens protein that is down-regulated in many cancers, but has been shown to be up-regulated in primary human ovarian cancer. Our objective was to evaluate E-cadherin expression in the hen ovary and compare its expression to human ovarian cancer. METHODS White Leghorn hens aged 185 weeks (cancerous and normal) were used for sample collection. A human ovarian tumor tissue array was used for comparison to the human disease. E-cadherin mRNA and protein expression were analyzed in cancerous and normal hen ovaries by immunohistochemistry (IHC), Western blot, and quantitative real-time PCR (qRT-PCR). Tissue fixed in neutral buffered formalin was used for IHC. Protein from tissue frozen in liquid nitrogen was analyzed by Western blot. RNA was extracted from tissue preserved in RNAlater and analyzed by qRT-PCR. The human ovarian tumor tissue array was used for IHC. RESULTS E-cadherin mRNA and protein expression were significantly increased in cancerous hen ovaries as compared to ovaries of normal hens by qRT-PCR and Western blot. Similar expression of E-cadherin was observed by IHC in both human and hen ovarian cancer tissues. Similar E-cadherin expression was also observed in primary ovarian tumor and peritoneal metastatic tissue from cancerous hens. CONCLUSIONS Our findings suggest that the up-regulation of E-cadherin is an early defining event in ovarian cancer and may play a significant role in the initial development of the primary ovarian tumor. E-cadherin also appears to be important in the development of secondary tumors within the peritoneal cavity. Our data suggest that E-cadherin may prove to be an important target in the preventative treatment of metastatic ovarian cancer and further confirm that the laying hen is a good model for the study of human epithelial ovarian carcinoma.


Gynecologic Oncology | 2008

Selenium-Binding Protein 1 expression in ovaries and ovarian tumors in the laying hen, a spontaneous model of human ovarian cancer

Karen Stammer; Seby L. Edassery; Animesh Barua; Pincas Bitterman; Janice M. Bahr; Dale B. Hales; Judith L. Luborsky

OBJECTIVE Reduced Selenium-Binding Protein 1 (SELENBP1) expression was recently shown in multiple cancers. There is little information on the expression and function of SELENBP1 in cancer progression. In order to develop a better understanding of the role of SELENBP1 in ovarian cancer, our objective was to determine if SELENBP1 is expressed in the normal ovaries and ovarian tumors in the egg-laying hen, a spontaneous model of human ovarian cancer. METHODS SPB1 mRNA expression in normal ovary (n=20) and ovarian tumors (n=23) was evaluated by RT-PCR. Relative levels of mRNA were compared by quantitative RT-PCR (qRT-PCR) in selected samples. SELENBP1 protein expression was evaluated by 1D Western blot and immunohistochemistry with a commercial anti-human SELENBP1 antibody. RESULTS SELENBP1 mRNA and protein was expressed in 100% of normal and ovarian tumors and qRT-PCR confirmed decreased mRNA expression in 80% of ovarian tumors. SELENBP1 was primarily localized in surface epithelial cells of normal ovaries. In ovaries containing early tumor lesions, SELENBP1 expression was reduced in the surface epithelium near the tumor and was expressed in tumor cells, while more distant regions with normal histology retained SELENBP1 expression in the surface epithelium. CONCLUSIONS We have shown for the first time that SELENBP1 is expressed in both normal ovaries and ovarian tumors in the hen and that SELENBP1 expression is altered in the vicinity of the tumor. Furthermore, SELENBP1 expression in normal ovarian surface epithelium and in ovarian tumors parallels that previously reported for ovarian cancer in women.


Worlds Poultry Science Journal | 1997

Rural poultry keeping in Bangladesh

Animesh Barua; Yukinori Yoshimura

In Bangladesh indigenous poultry have been kept by rural communities for many generations. This custom is likely to continue and remain popular in rural areas. The rural poultry system relies on mi...


Journal of Ultrasound in Medicine | 2010

Detection of Tumor-Associated Neoangiogenesis by Doppler Ultrasonography During Early-Stage Ovarian Cancer in Laying Hens A Preclinical Model of Human Spontaneous Ovarian Cancer

Animesh Barua; Pincas Bitterman; Janice M. Bahr; Michael J. Bradaric; Dales B. Hales; Judith L. Luborsky; Jacques S. Abramowicz

Objective. Tumor‐associated neoangiogenesis (TAN) is one of the earliest events in ovarian tumor growth and represents a potential target for early detection of ovarian cancer (OVCA). Because it is difficult to identify patients with early‐stage OVCA, the goal of this study was to explore a spontaneous animal model of in vivo ovarian TAN associated with early‐stage OVCA detectable by Doppler ultrasonography (DUS). Methods. White Leghorn laying hens were scanned transvaginally at 15‐week intervals up to 45 weeks. Gray scale ovarian morphologic characteristics and Doppler indices were recorded. Hens were euthanized at diagnosis for ultrasonographic morphologic/vascular abnormalities or at the end of the study (those that remained normal). Ovarian morphologic and histologic characteristics were evaluated. Vascular endothelial growth factor (VEGF) and αvβ3‐integrin expression was assessed by immunohistochemical analysis. Doppler ultrasonographic observations were compared with histologic and immunohisto‐chemical findings to determine the ability of DUS to detect ovarian TAN. Results. Significant changes in ovarian blood flow parameters were observed during transformation from normal to tumor development in the ovary (P < .05). Tumor‐related changes in ovarian vascularity were identified by DUS before the tumor became detectable by gray scale imaging. Increased expression of VEGF and αvβ3‐integrins was associated with tumor development. Ovarian TAN preceded tumor progression in hens. Conclusions. The results suggest that ovarian TAN may be an effective target for the detection of early‐stage OVCA. The laying hen may also be useful for studying the detection and inhibition of ovarian TAN using various means, including the efficacy of contrast agents, targeted molecular imaging, and antiangiogenic therapies.


Journal of Ultrasound in Medicine | 2007

Detection of Ovarian Tumors in Chicken by Sonography A Step Toward Early Diagnosis in Humans

Animesh Barua; Jacques S. Abramowicz; Janice M. Bahr; Pincas Bitterman; Angela L. Dirks; Keith A. Holub; Eyal Sheiner; Michael J. Bradaric; Seby L. Edassery; Judith L. Luborsky

Animal models of spontaneous ovarian cancer are important for understanding early tumor development. Ovarian imaging may play an important role in following changes in tumor development. Laying hens are the only animals that develop spontaneous ovarian cancer similar to humans. The aim of this study was to determine the feasibility of detecting ovarian tumors in laying hens using sonography.


American Journal of Reproductive Immunology | 2007

Anti‐tumor and Anti‐ovarian Autoantibodies in Women with Ovarian Cancer

Animesh Barua; Michael J. Bradaric; Tewabe Kebede; Sara Espionosa; Seby L. Edassery; Pincas Bitterman; Jacob Rotmensch; Judith L. Luborsky

There is a lack of validated marker(s) for the diagnosis of early‐stage ovarian cancer (OVCA). The objective was to determine if women with OVCA had antibodies, to assess their potential as markers of ovarian cancer. The secondary objective was to compare the prevalence of antibodies to proteins from normal ovary and ovarian tumors to determine if antibodies primarily recognize tumor antigens, as many antigens are common to tumor and normal ovary.


International Journal of Gynecological Cancer | 2009

Prevalence of antitumor antibodies in laying hen model of human ovarian cancer.

Animesh Barua; Seby L. Edassery; Pincas Bitterman; Jacques S. Abramowicz; Angela L. Dirks; Janice M. Bahr; Dale B. Hales; Michael J. Bradaric; Judith L. Luborsky

Antitumor antibodies are associated with tumors in human cancers. There is relatively little information on the timing and progression of antibody response to tumors. The objective of the study was to determine if spontaneous ovarian cancer in the egg-laying hen is associated with antitumor antibodies. Antibodies were detected by immunoassay and immunoblotting using proteins from normal ovary and ovarian tumors. Candidate antigens were identified by mass spectrometry of immunoreactive spots cut from 2-dimensional gels and Western blot. Antitumor (serum reacting against tumor ovarian extract) and antiovarian (serum reacting against normal ovarian extract) antibodies were significantly associated with ovarian cancer (67%; P ≤ 0.001) compared with normal control hens. Hens with abnormal histology but no gross tumor had antitumor antibodies (63%; P ≤ 0.025) but not antiovarian antibodies. There were common as well as different immunoreactions against normal ovary and homologous and heterologous tumor proteins in 2-dimensional Western blots. The candidate antigens included those commonly associated with human cancers and other diseases such as vimentin, apolipoprotein A1, Annexinn II, enolase, DJ-1, and so on. The results suggest that antitumor antibodies are associated with ovarian cancer in hens, similar to human ovarian cancer. The egg-laying hen may be a model for understanding the antitumor humoral immune response, particularly at early tumor stages that are not readily accessible in human ovarian cancer.

Collaboration


Dive into the Animesh Barua's collaboration.

Top Co-Authors

Avatar

Pincas Bitterman

Rush University Medical Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Sanjib Basu

Rush University Medical Center

View shared research outputs
Top Co-Authors

Avatar

Seby L. Edassery

Rush University Medical Center

View shared research outputs
Top Co-Authors

Avatar

Judith L. Luborsky

Rush University Medical Center

View shared research outputs
Top Co-Authors

Avatar

Aparna Yellapa

Rush University Medical Center

View shared research outputs
Top Co-Authors

Avatar

Sameer Sharma

Rush University Medical Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Michael J. Bradaric

Rush University Medical Center

View shared research outputs
Top Co-Authors

Avatar

Dale B. Hales

Southern Illinois University Carbondale

View shared research outputs
Researchain Logo
Decentralizing Knowledge